New study tests extra treatments for kids whose nearsightedness keeps getting worse despite special lenses

NCT ID NCT07494799

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will enroll about 3,890 children aged 8-12 who still have rapidly worsening nearsightedness (myopia) even after using orthokeratology (Ortho-K) lenses. Researchers will compare four approaches: continuing Ortho-K alone, adding low-dose atropine eye drops, using lenses with a smaller optical zone, or adding low-intensity red light therapy. The goal is to see which strategy best slows the lengthening of the eye over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

0.01% atropine sulfate eye drops; low-intensity red light therapy

What this could lead to

If successful, this could identify the best way to slow worsening nearsightedness in children who still progress despite wearing orthokeratology lenses.

What could go wrong

This is a prospective study that hasn't started recruiting yet. Results may not apply to all children, and some interventions (like atropine drops or red light) may cause side effects such as eye irritation or discomfort.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

degenerative myopia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••